Abstract
Many disturbances in the normal function of endoplasmic reticulum (ER) cause accumulation of unfolded proteins in the lumen of ER, triggering an evolutionary conserved response, termed the unfolded protein response (UPR). The UPR is the mechanism enabling cells to cope with unfolded proteins, accumulated in ER lumen after the cell has been exposed to various unfavorable conditions. The UPR process has strong prosurvival implications, but switches towards apoptotic cell death when the stress becomes severe and unsolvable. The hallmark of the cytoprotective branch of UPR is stimulation of the expression of ER chaperones, of which ORP150 has gained a great deal of attention. ORP150 has been identified as being overexpressed in the pathology of many diseases and is involved in the cellular response to environmental stress. Although some fragmentary results concerning ORP150 molecular activity have been presented, its exact mode of action still remains unclear. In this paper we focused on the role of ORP150 in the pathogenesis of the main types of ER stress-related diseases: diabetes, neurodegenerative diseases, cardiovascular diseases and cancer.
Keywords: ORP150, ER stress, unfolded protein response, diabetes, neurodegenerative diseases, cardiovascular diseases, cancer
Current Pharmaceutical Design
Title:Molecular Chaperone ORP150 in ER Stress–related Diseases
Volume: 19 Issue: 15
Author(s): Magdalena Kusaczuk and Marzanna Cechowska-Pasko
Affiliation:
Keywords: ORP150, ER stress, unfolded protein response, diabetes, neurodegenerative diseases, cardiovascular diseases, cancer
Abstract: Many disturbances in the normal function of endoplasmic reticulum (ER) cause accumulation of unfolded proteins in the lumen of ER, triggering an evolutionary conserved response, termed the unfolded protein response (UPR). The UPR is the mechanism enabling cells to cope with unfolded proteins, accumulated in ER lumen after the cell has been exposed to various unfavorable conditions. The UPR process has strong prosurvival implications, but switches towards apoptotic cell death when the stress becomes severe and unsolvable. The hallmark of the cytoprotective branch of UPR is stimulation of the expression of ER chaperones, of which ORP150 has gained a great deal of attention. ORP150 has been identified as being overexpressed in the pathology of many diseases and is involved in the cellular response to environmental stress. Although some fragmentary results concerning ORP150 molecular activity have been presented, its exact mode of action still remains unclear. In this paper we focused on the role of ORP150 in the pathogenesis of the main types of ER stress-related diseases: diabetes, neurodegenerative diseases, cardiovascular diseases and cancer.
Export Options
About this article
Cite this article as:
Kusaczuk Magdalena and Cechowska-Pasko Marzanna, Molecular Chaperone ORP150 in ER Stress–related Diseases, Current Pharmaceutical Design 2013; 19 (15) . https://dx.doi.org/10.2174/1381612811319150016
DOI https://dx.doi.org/10.2174/1381612811319150016 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Gut Microbiota in Human Health and Diseases
Current Nutrition & Food Science Population Diversity and its Relationship with Infectious and Tumor Diseases
Current Immunology Reviews (Discontinued) DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Genetics of Bladder Malignant Tumors in Childhood
Current Genomics The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers
Current Molecular Medicine Role of miR-193a in Cancer: Complexity and Factors Control the Pattern of its Expression
Current Cancer Drug Targets Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Current Drug Targets Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets The Use of the Bone Seeking Radiopharmaceutical 153-Samarium-EDTMP as an Adjuvant Treatment for Osteosarcoma: A Review
Current Medical Imaging Melanin-Concentrating Hormone Receptor 1 Antagonists: A New Perspective for the Pharmacologic Treatment of Obesity
Current Medicinal Chemistry Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Targeting Epithelial-Mesenchymal Transition Phenotype for Gastro-Intestinal Cancer
Current Pharmaceutical Design Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets